SGLT2 inhibitors increase the risk of Fournier’s gangrene by flooding the urinary tract with glucose, which creates a favorable environment for bacteria to thrive in the genital and perineal area. The connection is rare but serious enough that the FDA added a warning to all drugs in this class. Here’s how the chain of events works, how likely it actually is, and what to watch for.
How These Drugs Change Your Urinary Chemistry
SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and bexagliflozin) work by blocking a protein in the kidneys that normally reclaims glucose from urine and sends it back into the bloodstream. Blocking that protein reduces glucose reabsorption by 30% to 60%, which means a significant amount of sugar passes straight through into the urine instead of being recycled. That’s the intended effect: blood sugar drops, and the excess glucose leaves the body when you urinate.
The trade-off is that your urine now carries far more sugar than it normally would. This glucose-rich urine bathes the urethra, genital skin, and perineal area every time you urinate. For most people, this causes no problems beyond a slightly higher rate of yeast infections or urinary tract infections. But in a small number of cases, it sets the stage for something much more dangerous.
From Sugar-Rich Urine to Tissue Destruction
Fournier’s gangrene is a rapidly spreading infection of the soft tissue in the genital and perineal region (the area between the genitals and rectum). It’s caused by a mix of bacteria working together, including common species like E. coli, Staph aureus, Strep, Klebsiella, and anaerobic bacteria like Bacteroides and Clostridium. Normally, your skin and immune system keep these organisms in check.
The proposed mechanism connecting SGLT2 inhibitors to Fournier’s gangrene involves several steps:
- Chronic glycosuria. The persistent high concentration of glucose in urine provides a steady food source for bacteria in the genital and urinary area.
- Frequent low-grade infections. SGLT2 inhibitor users experience more urinary tract infections and genital yeast infections than people on other diabetes medications. These infections can cause small breaks in the skin or mucous membranes.
- Bacterial invasion. Once bacteria enter through damaged tissue, the warm, moist, sugar-rich environment of the perineal area allows them to multiply rapidly. Multiple species can colonize simultaneously.
- Necrotizing spread. The infection destroys soft tissue and cuts off its own blood supply, which makes it harder for the immune system and antibiotics to reach the affected area. The tissue death accelerates.
In short, the drugs don’t directly cause the infection. They alter the local chemistry of the genital area in a way that makes it easier for an infection to take hold and harder for the body to contain it before it becomes dangerous.
How Rare Is This Actually?
Extremely rare. A meta-analysis of 84 randomized controlled trials covering more than 69,000 patients found no statistically significant difference in Fournier’s gangrene rates between SGLT2 inhibitor users and comparison groups. The odds ratio was 0.41, meaning the data didn’t support a higher rate in the drug group, though the number of cases was so small that drawing firm conclusions either way is difficult.
The FDA issued its safety warning based on cases reported to its adverse event database, not from clinical trial data. The agency felt the severity of the condition warranted a label change even though the absolute number of reports was small. This is a case where a very serious outcome, even if uncommon, justified heightened awareness.
Who Faces the Greatest Risk
Fournier’s gangrene was a recognized complication of diabetes long before SGLT2 inhibitors existed. The main risk factors are poorly controlled type 2 diabetes, obesity, smoking, heavy alcohol use, immunosuppression (including HIV), and male sex. In published case reports of Fournier’s gangrene linked to SGLT2 inhibitors, patients consistently had overlapping risk factors: obesity, a long history of poorly controlled diabetes, and tobacco use.
This means the drug alone is unlikely to cause the condition. It adds one more variable, chronic glycosuria, on top of an already elevated baseline risk. If you have several of these risk factors, the additional glucose exposure in the genital area may be the tipping point that allows an infection to escalate.
Warning Signs to Recognize Early
Fournier’s gangrene progresses fast, sometimes within hours. The earliest symptoms include tenderness, redness, or swelling anywhere in the genital area or the skin between the genitals and rectum. A fever above 100.4°F, a general feeling of being unwell, or pain that seems much worse than the visible skin changes would suggest are all red flags. That last sign, pain out of proportion to what you can see, is a hallmark of necrotizing soft tissue infections and should prompt immediate medical attention.
Treatment requires emergency surgery to remove the dead tissue, combined with broad-spectrum antibiotics. The SGLT2 inhibitor is stopped immediately. Recovery can be lengthy and may involve multiple surgeries, but early detection dramatically improves outcomes.
Reducing Your Risk While on SGLT2 Inhibitors
Good perineal hygiene is the most practical step you can take. Keeping the genital area clean and dry reduces the bacterial load that the extra urinary glucose might otherwise feed. This means washing daily, drying thoroughly, and changing out of damp clothing promptly. In hot, humid climates, some people use antifungal powders in the perineal area as a preventive measure.
Paying attention to minor infections matters too. Yeast infections and urinary tract infections are more common on these drugs, and while they’re usually harmless on their own, they can create the small tissue breaks that let deeper infections begin. Treating them promptly, rather than waiting them out, reduces the chance of escalation. If you notice any unusual tenderness, swelling, or redness in the genital area that doesn’t resolve quickly, that warrants a call to your doctor rather than a wait-and-see approach.